Asset

Osugacestat

Alector Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (1)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT04111666phase1completed2019-12-142022-06-09Alector Inc.A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)